Next Article in Journal
A Prognostic Nomogram Based on Log Odds of Positive Lymph Nodes to Predict Overall Survival for Non-Metastatic Bladder Cancer Patients after Radical Cystectomy
Previous Article in Journal
Issues and Prospects of Current Endoscopic Treatment Strategy for Superficial Non-Ampullary Duodenal Epithelial Tumors
 
 
Article

The Challenges of Patient Selection for Prostate Cancer Focal Therapy: A Retrospective Observational Multicentre Study

1
Urology Clinic, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy
2
Chirurgie Urologique, Hôpital Croix Saint Simon Groupe Diaconesses, 75020 Paris, France
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(10), 6826-6833; https://doi.org/10.3390/curroncol29100538
Received: 31 August 2022 / Revised: 13 September 2022 / Accepted: 20 September 2022 / Published: 22 September 2022
(This article belongs to the Topic Prostate Cancer: Symptoms, Diagnosis & Treatment)
Increased diagnoses of silent prostate cancer (PCa) have led to overtreatment and consequent functional side effects. Focal therapy (FT) applies energy to a prostatic index lesion treating only the clinically significant PCa focus. We analysed the potential predictive factors of FT failure. We collected data from patients who underwent robot-assisted radical prostatectomy (RARP) in two high-volume hospitals from January 2017 to January 2020. The inclusion criteria were: one MRI-detected lesion with a Gleason Score (GS) of ≤7, ≤cT2a, PSA of ≤10 ng/mL, and GS 6 on a random biopsy with ≤2 positive foci out of 12. Potential oncological safety of FT was defined as the respect of clinicopathological inclusion criteria on histology specimens, no extracapsular extension, and no biochemical, local, or metastatic recurrence within 12 months. To predict FT failure, we performed uni- and multivariate logistic regression. Sixty-seven patients were enrolled. The MRI index lesion median size was 11 mm; target lesions were ISUP grade 1 in 27 patients and ISUP grade 2 in 40. Potential FT failure occurred in 32 patients, and only the PSA value resulted as a predictive parameter (p < 0.05). The main issue for FT is patient selection, mainly because of multifocal csPCa foci. Nevertheless, FT could represent a therapeutic alternative for highly selected low-risk PCa patients. View Full-Text
Keywords: prostate cancer; focal therapy; low-risk PCa; MRI; PSA prostate cancer; focal therapy; low-risk PCa; MRI; PSA
MDPI and ACS Style

Paladini, A.; Cochetti, G.; Colau, A.; Mouton, M.; Ciarletti, S.; Felici, G.; Maiolino, G.; Balzarini, F.; Sèbe, P.; Mearini, E. The Challenges of Patient Selection for Prostate Cancer Focal Therapy: A Retrospective Observational Multicentre Study. Curr. Oncol. 2022, 29, 6826-6833. https://doi.org/10.3390/curroncol29100538

AMA Style

Paladini A, Cochetti G, Colau A, Mouton M, Ciarletti S, Felici G, Maiolino G, Balzarini F, Sèbe P, Mearini E. The Challenges of Patient Selection for Prostate Cancer Focal Therapy: A Retrospective Observational Multicentre Study. Current Oncology. 2022; 29(10):6826-6833. https://doi.org/10.3390/curroncol29100538

Chicago/Turabian Style

Paladini, Alessio, Giovanni Cochetti, Alexandre Colau, Martin Mouton, Sara Ciarletti, Graziano Felici, Giuseppe Maiolino, Federica Balzarini, Philippe Sèbe, and Ettore Mearini. 2022. "The Challenges of Patient Selection for Prostate Cancer Focal Therapy: A Retrospective Observational Multicentre Study" Current Oncology 29, no. 10: 6826-6833. https://doi.org/10.3390/curroncol29100538

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop